(Q54081613)

24 May 2018

title

Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine. (English)

1 reference

24 May 2018

1 reference

1 reference

9

Chetrit A

1 reference

24 May 2018

11

Ben-Bassat I

1 reference

24 May 2018

author name string

Raanani P

1

1 reference

24 May 2018

Shpilberg O

2

1 reference

24 May 2018

Gillis S

3

1 reference

24 May 2018

Avigdor A

4

1 reference

24 May 2018

Hardan I

5

1 reference

24 May 2018

Berkowicz M

6

1 reference

24 May 2018

Sofer O

7

1 reference

24 May 2018

Lossos I

8

1 reference

24 May 2018

Ben-Yehuda D

10

1 reference

24 May 2018

publication date

1 August 1999

1 reference

24 May 2018

published in

Leukemia Research

1 reference

24 May 2018

volume

23

1 reference

24 May 2018

issue

8

1 reference

24 May 2018

page(s)

695-700

1 reference

24 May 2018

Acute Leukemia: Biology and Treatment

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

Treatment strategies in acute myeloid leukemia (AML). A. First-line chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

Treatment of resistant acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

Treatment of relapsed and refractory acute myelogenous leukaemia with aclacinomycin A (ACA) and etoposide (VP-16).

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

Mitoxantrone in the treatment of relapsed and refractory acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

Response to salvage therapy and survival after relapse in acute myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

Mitoxantrone and intermediate‐dose cytosine arabinoside for poor‐risk acute leukemias: Response to treatment and factors influencing outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2899%2900078-8

7 January 2021

10.1016/S0145-2126(99)00078-8

Identifiers

DOI

1 reference

24 May 2018

1 reference

24 May 2018